Pondurance Ranked #8 Top Cybersecurity Company of 2025
Software Report Named Pondurance 8th most Innovative and Impactful Cybersecurity Player Addressing Pressing Digital Threats
WASHINGTON, June 16, 2025--(BUSINESS WIRE)--Pondurance, the leading provider of managed detection and response (MDR) cybersecurity services designed to minimize breach risks, today announced that they were ranked #8 in the recently released Top 25 Cybersecurity Companies of 2025 by Software Report. This coincides with Pondurance launching a new website making it easier for organizations to navigate their journey for selecting an optimal managed security solution.
In addition to its multiple award-winning managed detection and response (MDR) service, Pondurance also provides best-in-class digital forensics and incident response (DFIR) services, exposure and vulnerability services, and an extensive array of cybersecurity and compliance professional services offerings.
"2025 has been a pivotal year for Pondurance. We've innovated our risk-based MDR platform while maintaining relentless focus on providing the kind of personalized service unavailable from the big-box cybersecurity players," said Doug Howard, CEO and president of Pondurance. "By addressing everpresent breach risks and cybersecurity threats for organizations with regulated data, Pondurance has cracked the code for rapid growth and operational excellence in a confusing cybersecurity market."
Pondurance is unique in having developed a risk-based, cloud-native platform and using that specifically to provide managed security services for organizations that need to rely on a trusted party for its security technology and operational needs. By combining new exposure & vulnerability capabilities, a next-generation managed SIEM, and a best-in-class MDR service, with its US-based, 24/7 security operations center (SOC), incident response (IR), and security services teams, Pondurance stands alone in the breach risk protection it offers its customers.
The award-winning Pondurance MDR service is now available for a limited time 30-day free trial for new qualified customers. This comes complete with a next-generation managed SIEM and an entirely U.S.-based 24/7 security operations center (SOC). To learn more about this offer, visit https://www.pondurance.com/30-day-free-trial.
Additional Resources
Join the conversation with Pondurance on Linkedin, YouTube, and Bluesky
To learn more about the Pondurance MDR, incident response and cyber advisory services, visit pondurance.com.
Interested in becoming a Pondurance Partner? Apply today
About Pondurance
Pondurance is the only provider of managed detection and response (MDR) services specifically engineered to minimize breach risks. As a full-service provider of incident response (DFIR), MDR, exposure management, and cybersecurity advisory and compliance services, Pondurance protects mid-sized organizations from data breach before, during and after they occur. Organizations entrusted with consumer PHI and PII rely on Pondurance to provide a unified platform and outsourced security operations center (SOC) service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616560559/en/
Contacts
Media ContactLaura Le888-385-1702Laura.le@pondurance.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
34 minutes ago
- San Francisco Chronicle
Indonesian coal industry risking a tough transition as demand declines, report says
HANOI, Vietnam (AP) — Indonesia's coal industry is facing mounting pressure and should diversify as China and India, its biggest customers, cut back on imports of the heavily polluting fossil fuel, according to a report from a Jakarta-based energy thinktank, Energy Shift. The report released Tuesday says that the industry, which accounts for about 3.6% of Indonesia's economic activity and employs tens of thousands of people, needs to shift toward cleaner energy now or risk being forced into a costly transition later. Indonesia is the world's biggest exporter of coal, which is central to its economy, generating tax revenues and jobs. So the expected long-term decline in demand presents a unique challenge for the country of some 280 million. Indonesia's coal production is still rising, hitting a record 836 million tons in 2024, nearly 8% more than the year before. The industry also relies heavily on just a few buyers, with China and India buying nearly two-thirds of Indonesia's coal exports in 2023. China still relies on coal for more than half its electricity generation. It accounted for 41% of global coal imports in 2024, or nearly 543 million tons. But more than 75% of the growth in demand last year was met by clean energy. India's coal imports fell 8.4% to 183.42 million metric tons from April to December 2024, down from 200.19 million metric tons in the same period a year earlier, government data shows. The drop is part of India's push to reduce import dependence by ramping up domestic coal production. Imports for industries like cement, steel and aluminum that buy coal at market rates declined 12% while imports for thermal power plants fell even more sharply, down 29.8%. Indonesia's coal exports fell to a three-year low in January-April of this year, a shift that may signal a longer term decline, experts say. 'These are signs that Indonesian coal miners have to start taking seriously as well,' said Hazel Ilango of the Energy Shift Institute. There are other risks too. Most Indonesian coal companies are tightly controlled by insiders — owners, executives, and board members — who hold about 75% of company shares on average, according to the report. Regulations such as domestic supply rules and high royalties also limit profits, while access to global financing remains restricted. The private sector and investors are generally uninterested in long-term transition plans and are more focused on immediate profits, while government policies remain inconsistent, said Putra Adhiguna of the Energy Shift Institute. Experts say that the country's coal policy is riddled with contradictions. It has pledged to cut emissions and transition to clean energy, but it continues to expand coal production and approve new plants. Domestic subsidies keep coal cheap, but abrupt export bans have disrupted global markets. Meanwhile, the state utility plans to retire coal plants early under a $20 billion transition deal — even as new ones tied to the industry are still being built. As major coal importers like China and India cut imports to boost their energy security, Indonesia's coal sector needs to plan ahead, said Jordan Lee, an energy transition expert at the Tony Blair Institute for Global Change in Jakarta. 'The reason I say that is basically if you look at what happened with some big oil companies that have tried something similar, we have seen the market not respond too positively,' he said. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
Business Wire
44 minutes ago
- Business Wire
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the publication of preclinical data in Nature Communications demonstrating that its lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioral symptoms in a non-human primate model. The findings support the continued clinical development of ART5803 as a first-in-class, targeted therapeutic. The company is currently completing Phase 1 safety studies for ART5803 and plans Phase 2 evaluation in anti-NMDA receptor encephalitis (ANRE) and autoimmune psychosis patients in the second half of 2025. 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. Share 'This study underscores the promise of ART5803 to directly address neuropsychiatric disease caused by anti-NMDA receptor-targeting pathogenic antibodies,' said Peter Flynn, Ph.D. President and CEO of Arialys Therapeutics. 'Despite our understanding of the disease mechanism and its severity, ANRE lacks an approved therapy. Further, there is a growing body of data identifying significant levels of anti-NMDA receptor autoantibodies in subpopulations of patients diagnosed with diseases that result in psychosis and dementia.' 'These data provide compelling evidence that ART5803 can directly block the pathogenic effect of autoantibodies that target the NMDA receptor, resulting in a rapid resolution of symptoms,' said Mitsuyuki (Mickey) Matsumoto, Ph.D., Chief Scientific Officer of Arialys Therapeutics and senior author of the paper. 'Our detailed structural and functional analyses confirm that ART5803 precisely inhibits NMDA receptor internalization induced by the pathogenic autoantibodies, while preserving normal receptor function. In addition, our discovery of a potential molecular mimicry mechanism for anti-NMDA receptor autoantibody generation broadens the understanding of disease initiation and may inform future indication expansion for ART5803.' Anti-NMDA receptor encephalitis (ANRE) is a rare, potentially lethal, poorly managed, and often misdiagnosed neurological disease. ANRE is caused by pathogenic autoantibodies that bind to and crosslink NMDA receptors in the brain, leading to receptor internalization and synaptic dysfunction. The result is a range of debilitating neuropsychiatric symptoms including psychiatric and behavioral alterations, cognitive decline, seizures, coma, and diminished autonomic function. A significant percentage of ANRE patients are pediatric, where NMDA receptor-specific autoantibodies can also result in neurological development deficits. There are no approved therapies for this disease, and current treatments rely on broadly immunosuppressive therapies, which are associated with delayed efficacy and significant side effects. Recent findings have also identified anti-NMDA receptor autoantibodies in other neurological and psychiatric diseases such as schizophrenia, depression, bipolar disorder, and dementia. Arialys is planning clinical assessment of ART5803 in anti-NMDA receptor autoantibody-positive psychosis patients. The company is also currently testing patient samples using a proprietary high-throughput screen for autoantibodies to identify enriched disease indications and subpopulations for future clinical development. ART5803 is a humanized, monovalent IgG1 antibody engineered to selectively bind the GluN1 subunit of the NMDA receptor without disrupting receptor function or causing internalization. In this study, ART5803 demonstrated the ability to potently block NMDA receptor internalization in cellular and neuronal models and reversed both molecular and behavioral hallmarks of disease in a novel marmoset model of ANRE. Notably, ART5803 exhibited rapid onset of action and was well tolerated in vivo. The publication also includes a detailed characterization of ART5803's binding epitope, its mechanism of action, and population pharmacokinetic modeling supporting the feasibility of systemic administration in patients. In addition to demonstrating the therapeutic potential of ART5803, the paper revealed a potential link between infections—specifically Toxoplasma gondii and certain bacterial pathogens—and the generation of pathogenic anti-NMDA receptor autoantibodies. Epitope mapping analysis identified regions of potential molecular mimicry between microbial proteins and the GluN1 subunit of the NMDA receptor, suggesting that infections could serve as environmental triggers for disease initiation. Notably, toxoplasmosis and bacterial infections are well-established risk factors for a range of neuropsychiatric conditions. These findings not only suggest a basis for disease pathogenesis but also support broader therapeutic opportunities for ART5803 across autoimmune neuropsychiatric disorders. ART5803 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers. In February 2025, Arialys announced completion of all single ascending dose (SAD) cohorts and initiation of multiple ascending dose (MAD) cohorts. The company expects to share initial clinical data in the second half of 2025 and initiate Phase 2 proof-of-concept studies. The publication was completed in collaboration with researchers from Astellas Pharma Inc., University of California, Davis, Kitasato University School of Medicine, and Vanadro LLC. About Arialys Therapeutics Arialys was founded by investors Avalon Bioventures, Catalys Pacific and MPM to meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease. Using a combination of highly sensitive autoantibody detection, patient sampling and receptor structural biology, Arialys has developed a first-in-class precision therapy to specifically block pathogenic autoantibodies in the brain. Arialys is headquartered in La Jolla, California. For more information, visit
Business Wire
44 minutes ago
- Business Wire
AXL Launches Venture Studio with $15M to Build 50 AI Companies, Fuelling Canada's Global Leadership in AI Research-to-Commercialization
TORONTO--(BUSINESS WIRE)--Today, AXL, a new Canadian venture studio transforming world-class AI research into high-growth companies, has launched with a plan to build 50 AI-powered companies over the next five years to fuel Canada's research-to-commercialization pipeline. This is enabled by an oversubscribed first closing of its venture fund of $15 million CAD. With this, AXL will form and scale homegrown innovation — and keep it here. Daniel Wigdor, one of Canada's top innovators and AXL's Co-Founder and CEO, is reinvesting back into the Canadian tech ecosystem as the fund's lead investor, following the sale of his previous company, Chatham Labs, to Meta, where he served as the founding director of their Toronto research centre. AXL is also backed by a coalition of successful Canadian entities and strategic industry investors rallying around the future of AI in Canada, including David Martin, Founder of Smart Technologies; Gord Kurtenbach, former Head of Autodesk Research; Joshua Greer, Founder of Real-D; Frank Mersch, Chief Investment Officer and Senior Portfolio Manager of Front Street Capital; Rob McEwen, Chairman and Chief Owner of McEwen Mining; and many of Canada's leading professors in applied AI. As the global AI race heats up, Canada faces mounting pressure to retain its intellectual property and top talent to secure its leadership. Over the past decade, American firms have acquired 70 Canadian AI companies and counting, while Silicon Valley firms have opened large local offices, resulting in the loss of valuable intellectual property and potential upside. According to a study by Element AI in 2018, Canada experienced a net talent outflow, underscoring the challenge of retaining its top AI minds. 'Canada has a long history of pioneering breakthroughs, including AI, yet we've repeatedly failed to capture the value of our own innovations as our talent and biggest ideas scale somewhere else,' said Daniel Wigdor, Co-Founder and CEO of AXL. 'We're here to change that by connecting Canada's AI excellence with real market needs and the full-stack support that founders need to win globally.' Where research becomes scalable ventures Founded by a team of seasoned tech entrepreneurs and executives — Daniel Wigdor, Tovi Grossman, David Sharma, and Ray Sharma — AXL combines decades of experience scaling companies worldwide in a mission to bridge cutting-edge research with commercial success. AXL's proprietary venture studio model integrates access to AI research from the University of Toronto with market insights from Canada's top businesses through its AI Catalyst program. In this corporate partnership initiative, leading Canadian companies like Dillon Consulting partner with AXL to investigate how AI could reshape their businesses, often becoming the first customer and strategic investor in resulting ventures. This blend creates an environment where ventures are rooted in validated industry demand, supported by a full-stack team that manages everything from prototype and application development to legal, finance, sales, and growth strategies. 'Our corporate partnerships are the engine that transforms lab breakthroughs into ventures with real-world traction,' said David Sharma, Chief Growth Officer at AXL. 'By collaborating directly with Canada's private sector, we ensure that innovation is guided by genuine industry needs and positioned for rapid adoption. This approach closes a critical gap in Canada's innovation system, turning bright ideas into scalable solutions that deliver long-term value for our partners and the broader economy.' Seeing beyond the horizon NVIDIA's Jensen Huang has called Canada the 'Epicentre of Modern AI,' but what's lesser known is Canada's leadership in applied computing, the field that converts foundational research into practical tools. Applied computing bridges the gap between advanced technology and everyday life, making advanced technology more accessible to all. 'The transformative power of AI will come from impactful, practical applications, not just large models or infrastructure,' said Wigdor. 'Focusing solely on building bigger models risks missing the real opportunities in creating tools that genuinely empower people and open new possibilities in our daily lives.' Canada's 'AI moment' is here. It's a once-in-a-generation opportunity to fundamentally shift the balance of power in the tech industry. While the rest of the world rushes to commoditize infrastructure, AXL can see past that horizon by investing in the application layer, well beyond what Silicon Valley is currently betting on. 'If we do this right, we won't be saying things like 'Toronto is the Silicon Valley of Ontario.' Two decades from now, San Francisco will be trying to brand itself the 'Toronto of California,'' added Wigdor. Canada's path to a self-sustaining, world-leading AI ecosystem AXL is committed to nurturing a new generation of founders by providing capital, mentorship, operations, and the infrastructure necessary to turn ideas into impactful ventures, with the broader mission of creating a thriving, self-sustaining AI ecosystem that retains talent, intellectual property, and economic prosperity within Canada. 'We believe that Canadian entrepreneurs deserve the opportunity to build and scale world-class AI-powered companies here at home,' added Wigdor. 'With AXL, we're creating the infrastructure and community needed to transform innovation into lasting impact.' To learn more about how AXL is fuelling Canada's AI research to commercialization pipeline, visit their website at ABOUT AXL AXL is a Canadian venture studio transforming world-class research into high-growth companies that shape the future of applied AI. Led by seasoned tech entrepreneurs and applied AI experts, AXL's mission is to ensure Canada's top breakthroughs are built and scaled at home. By connecting academia with real market demand and full-stack venture creation, AXL helps Canada move from invention to impact, anchoring talent, intellectual property, and long-term economic value within the country.
